OraSure Technologies to Present at Stephens Annual Investment Conference
11/14/2022 - 07:05 AM
BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Ken McGrath, Chief Financial Officer, will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022 at 9:00 am ET. The conference will be simultaneously webcast over the Internet.
Live webcasts and replays of the presentations can be accessed by going to OraSure Technologies’ web site, www.orasure.com
About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com .
Company contacts
Investor Relations Contact:
Scott Gleasonsgleason@orasure.com
Media Contact:
Amy Kochmedia@orasure.com
Orasure Technologies Inc.
OSUR Rankings
#969 Ranked by Stock Gains
OSUR Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Bethlehem
About OSUR
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
